CEO's $46M IPO Windfall Not Fraud, Cancer Therapy Co. Says
NantKwest Inc. urged a California judge Wednesday to toss a putative investor class action alleging the cancer treatment company unlawfully hid that its CEO was eligible for $46 million in additional...To view the full article, register now.
Already a subscriber? Click here to view full article